BiologicalDrug
Barzolvolimab clinical trials
Also written CDX-0159.
Keep track of what changes. Save the barzolvolimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Studies
Open first, then newest update. How each study uses barzolvolimab is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)RecruitingPhase 3Celldex TherapeuticsNCT07266402Written as Barzolvolimab
- A Study of Barzolvolimab in Patients With Atopic DermatitisActive, not recruitingPhase 2Celldex TherapeuticsNCT06727552Written as Barzolvolimab
- A Study of Barzolvolimab in Patients With Prurigo NodularisActive, not recruitingPhase 2Celldex TherapeuticsNCT06366750Written as barzolvolimab
- A Study of CDX-0159 in Patients With Eosinophilic EsophagitisCompletedPhase 2Celldex TherapeuticsNCT05774184Written as barzolvolimab
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaActive, not recruitingPhase 3Celldex TherapeuticsNCT06445023Written as barzolvolimab
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Active, not recruitingPhase 3Celldex TherapeuticsNCT06455202Written as barzolvolimab
- A Study of CDX-0159 in Patients With Chronic Inducible UrticariaCompletedPhase 2Celldex TherapeuticsNCT05405660Written as barzolvolimab
- A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedPhase 2Celldex TherapeuticsNCT05368285Written as barzolvolimab
- A Study of CDX-0159 in Patients With Prurigo NodularisCompletedPhase 1Celldex TherapeuticsNCT04944862Written as CDX-0159
- A Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedPhase 1Celldex TherapeuticsNCT04538794Written as CDX-0159
- A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic UrticariaCompletedPhase 1Celldex TherapeuticsNCT04548869Written as CDX-0159
- A Phase 1 Study of Subcutaneous CDX-0159 in Healthy SubjectsCompletedPhase 1Celldex TherapeuticsNCT05031624Written as CDX-0159
- A Phase 1 Study of CDX-0159CompletedPhase 1Celldex TherapeuticsNCT04146129Written as CDX-0159
Given in every arm · 1 — barzolvolimab is usual care beside what is tested
Codes
What other systems call barzolvolimab · ClinicalTrials.gg INT014845
- UNII (FDA) 4B77GX0NA3BARZOLVOLIMABOne source FDA
- NCI Thesaurus C184860BarzolvolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4B77GX0NA3 | BARZOLVOLIMAB | One source FDA |
| NCI Thesaurus | C184860 | Barzolvolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.